Perigon Wealth Management LLC Has $3.83 Million Stake in Pfizer Inc. $PFE

Perigon Wealth Management LLC raised its position in Pfizer Inc. (NYSE:PFE) by 22.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 150,371 shares of the biopharmaceutical company’s stock after buying an additional 27,728 shares during the quarter. Perigon Wealth Management LLC’s holdings in Pfizer were worth $3,831,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC boosted its stake in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC boosted its stake in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares in the last quarter. WPG Advisers LLC bought a new stake in shares of Pfizer during the 1st quarter valued at approximately $35,000. Magnetar Financial LLC acquired a new position in Pfizer during the 1st quarter worth approximately $1,823,000. Finally, Vident Advisory LLC lifted its stake in Pfizer by 761.7% in the 1st quarter. Vident Advisory LLC now owns 80,414 shares of the biopharmaceutical company’s stock valued at $2,038,000 after purchasing an additional 71,082 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.3%

NYSE:PFE opened at $25.10 on Monday. The firm’s fifty day moving average is $25.16 and its 200-day moving average is $24.89. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69. The firm has a market cap of $142.68 billion, a P/E ratio of 14.59 and a beta of 0.46.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The business had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio is presently 100.00%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Wolfe Research set a $24.00 price objective on Pfizer and gave the company an “underperform” rating in a report on Wednesday, December 17th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a report on Wednesday, December 10th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Finally, UBS Group reissued a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $28.06.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.